-
Product Insights
NewNet Present Value Model: AnaptysBio Inc’s Imsidolimab
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's Imsidolimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: AnaptysBio Inc’s Rosnilimab
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's Rosnilimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: AnaptysBio Inc’s ANB-032
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's ANB-032 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Target KK-LC-1 for Oncology in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pomalidomide in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pomalidomide in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pomalidomide in Refractory Multiple Myeloma Drug Details:Pomalidomide is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ANB-032 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANB-032 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ANB-032 in Atopic Dermatitis (Atopic Eczema)Drug Details:ANB-032 is under development for...
-
Company Insights
Innovation and Patenting activity of AnaptysBio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AnaptysBio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Profile
AnaptysBio Inc – Company Profile
AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune...
Add to Basket -
Product Insights
Net Present Value Model: Imsidolimab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Imsidolimab Drug Details Imsidolimab (ANB-019) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – etokimab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry etokimab Drug Details Etokimab (ANB-020) was under development for the treatment of chronic rhinosinusitis...